Is it too late to buy these high-flying ASX shares?

The market may have been drifting notably lower of late, but not all shares have followed it lower.

In fact, some shares have even managed to climb to 52-week highs of better. Is it too late to buy these high-flying shares?

The Acrux Limited (ASX: ACR) share price rocketed 34% higher to a 52-week high of 31 cents today. This morning the company released an updated investor presentation highlighting its shift from being a one-trick pony to a pharmaceutical company with a diverse portfolio of 13 topical generic products with an addressable market of over US$1.4 billion. I think Acrux’s transformation has been very positive, however, I’d like to see how its sales fare over the next 12 months before considering an investment.

The ResApp Health Ltd (ASX: RAP) share price hit a 52-week high of 28 cents on Friday before being placed in a trading halt before the market opened on Monday. The digital healthcare company’s shares have been on fire this year thanks to a series of positive developments related to its Smartcough-C-2 and paediatric studies. Management appears to have seized on this strong share price rally by launching a capital raising this week. Although there has been no official word out of the company, the word on the street is that the company is aiming to raise $5 million at 22 cents per share. Surprisingly, just last week ResApp released a company update and stated that it was well-funded to execute its ongoing clinical strategy.

The Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) share price rose to an all-time high of $25.39 today. The investment house’s shares have climbed 9.5% since this time last month despite there being no news out of it. However, with its full year results release just a matter of days away, it appears that some investors are expecting another strong result from the company. While I do think that it is a quality share to own, I would prefer to get in at a lower price. In light of this, I would suggest investors hold out in hope of post-earnings share price weakness.

In the meantime, I would be buying this share which I think is trading at a very attractive price right now.

Motley Fool Australia Issues Rare "Double Down" Buy Alert

Scott Phillips has stumbled upon a little-owned stock he believes could be one of the greatest discoveries of his 25 years as a professional investor.


This is your chance to get in early on of what could prove to be a very special investment recommendation. Think about how many investing trends you've missed out on, even though you knew they were going to be big. Don't let that happen again. This is your chance to get in early.

Simply click here to get started and access our secure sign-up page.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Washington H. Soul Pattinson and Company Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!